ライフサイエンスコーパス: nitrosourea

1 th the alkylator agent 1,3-bis-chloroethyl-1-nitrosourea.

2 had been treated with the mutagen N-ethyl-N-nitrosourea.

3 was observed after treatment with N-ethyl-N-nitrosourea.

4 mouse mutation that was induced by N-ethyl-N-nitrosourea.

5 n the mouse Nell1 gene, induced by N-ethyl-N-nitrosourea.

6 fonate, N-propyl-N-nitrosourea and N-butyl-N-nitrosourea.

7 gs temozolomide and 1,3-bis(2-chloroethyl)-1-nitrosourea.

8 tment with the methylating agent, N-methyl-N-nitrosourea.

9 eous spectrum or that derived from N-ethyl,N-nitrosourea.

10 g agents such as cisplatin and bichloroethyl nitrosourea.

11 mbination of BG and 1,3-bis(2-chloroethyl)-1-nitrosourea.

12 mbination of BG and 1,3-bis(2-chloroethyl)-1-nitrosourea.

13 ea-type drugs, e.g. 1,3-bis(2-chloroethyl)-1-nitrosourea.

14 ation with 13 mg/m2 1,3-bis(2-chloroethyl)-1-nitrosourea.

15 r 2 x LD10 doses of 1,3-bis(2-chloroethyl)-1-nitrosourea.

16 reatment with the powerful mutagen N-ethyl-N-nitrosourea.

17 e or recurrent malignant glioma resistant to nitrosoureas.

18 astoma multiforme, and 11 had received prior nitrosoureas.

19 with the resistance of glioma cell lines to nitrosoureas.

20 esirable toxicophores contained in antitumor nitrosoureas.

21 and in the absence and presence of sublethal nitrosourea ([1-(2-chloroethyl)-3-cyclohexyl-l-nitrosour

22 onstrating a wider margin of safety than the nitrosourea, 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU)

23 Of 30 rats injected with N-methyl-N-nitrosourea, 17 developed mammary tumors.

24 h a strong DNA-alkylating mutagen, N-ethyl-N-nitrosourea, 55% of transgenic mice developed AML and th

25 hanced following administration of N-ethyl-N-nitrosourea, a carcinogen that induces DNA mutations.

26 the antitumor agent 1,3-bis(2-chloroethyl)-1-nitrosourea, a chemotherapeutic used to combat various b

27 Using N-ethyl-N-nitrosourea, a novel recessive mutation named seal was p

28 the GR inhibitor, 1,3 bis-(2 chloroethyl)-1-nitrosourea, abolished the inhibitory effect of flow.

29 N-methyl-N-nitrosourea accelerated tumor formation, and tumors deve

30 motherapy [25 mg/kg 1,3-bis(2-chloroethyl)-1-nitrosourea administered with a single i.p. injection] o

31 Five days following 1-methyl-1-nitrosourea administration, animals were fed ad libitum

32 sduced cells or 10% 1,3-bis(2-chloroethyl)-1-nitrosourea alone.

33 ious GR inhibitors, N,N-bis(2-chloroethyl)-N-nitrosourea, an anticancer drug with IC(50) = 647 microm

34 y rats were given an injection of 1-methyl-1-nitrosourea and fed purified diets ad libitum or at 60%

35 atally lethal mutations induced by N-ethyl-N-nitrosourea and mapped near Tyr are alleles of Fah.

36 HeLa cells against 1,3-bis(2-chloroethyl)-1-nitrosourea and methyl methanesulfonate cytotoxicity eit

37 stogenic effects of 1,3-bis(2-chloroethyl)-1-nitrosourea and mitomycin C (MMC), as measured by cell k

38 rosourea, ethyl methanesulfonate, N-propyl-N-nitrosourea and N-butyl-N-nitrosourea.

39 tant to DN, were mutagenized using N-ethyl-N-nitrosourea and screened for mutants that developed exce

40 a Lobund/Wistar rat treated with N-methyl-N-nitrosourea and testosterone propionate.

41 ouse mutagenesis with the chemical N-ethyl-N-nitrosourea and the strategy used to instantaneously ide

42 mice that were and were not given N-methyl-N-nitrosourea, and analyzed by histopathologic and molecul

43 eated with the chemical carcinogen N-ethyl-N-nitrosourea, and continuously passaged to yield cell pop

44 ivity to methyl methanesulfonate, N-methyl-N-nitrosourea, and the chemotherapeutic drugs temozolomide

45 plicates the use of N,N-bis(2-chloroethyl)-N-nitrosourea as a GR inhibitor.

46 ing water with or without 240 ppm N-methyl-N-nitrosourea at 5 weeks of age and thereafter on alternat

47 Rats were injected with N-methyl-N-nitrosourea at 7 weeks of age; 2 weeks later, the rats w

48 primary end point was successfully met using nitrosourea-based (pre-TMZ) chemotherapy era historic co

49 alkylating agents, including 2-chloroethyl-N-nitrosourea-based antitumor drugs.

50 mpared with historical controls who received nitrosourea-based chemotherapies.

51 No prospective comparison with nitrosourea-based chemotherapy exists.

52 onse to exposure to 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) alone; however, 70-80% of cells were

53 1omega) of low-dose 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) and a second group receiving two cycl

54 chemotherapy agents 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) and cis-diamminedichloroplatinum (cis

55 on of radiation and 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) chemotherapy in three primary human g

56 ons of diamide plus 1,3-bis(2 chloroethyl)-1-nitrosourea (BCNU) increased intracellular GSSG and decr

57 titumor efficacy of 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) is being tested in clinical trials.

58 ional DNA alkylator 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) is cytotoxic primarily by inducing DN

59 ens were used: vincristine, bis-chloro-ethyl nitrosourea (BCNU) melphalan, cyclophosphamide, and pred

60 exposure to either 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) or glutathione reductase-specific siR

61 g 6-BG and 10 mg/kg 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) or with 40 mg/kg BCNU alone.

62 chemotherapy using 1,3-bis-(2-chloroethyl)-1-nitrosourea (BCNU) resulted in similar increases in gene

63 to cell killing by 1,3-bis (2-chloroethyl)-1-nitrosourea (BCNU) than overexpression of nucl-MGMT.

64 B/c model followed by N,N-bis(2-chloroethyl)-nitrosourea (BCNU) treatment to enhance donor-cell engra

65 -linking reaction of N,N'-bis(2-chloroethyl)-nitrosourea (BCNU) were investigated using synthetic oli

66 nSOD (AdMnSOD) plus 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) would lead to an increased level of i

67 of temozolomide and 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU), and no further sensitization occurs

68 oreductase enzymes (1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU), arsenite, and phenylarsine oxide) su

69 mise its integrity (1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU), cisplatin, H(2)O(2) and UV rays) enh

70 In combination with 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU), the prodrugs were not effective adju

71 e of 35 mg/m(2) of N,N'-bis(2-chloroethyl)-N-nitrosourea (BCNU), which was otherwise ineffective as a

72 ing cell killing by 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU).

73 benzene (CDNB); or 1,3-bis (2-chloroethyl)-1-nitrosourea (BCNU).

74 an the nitrosourea, 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU).

75 an, and carmustine [1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU)] weakly induced luciferase activity i

76 of antitumor agent 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU, Carmustine) into biodegradable polyme

77 nd O6-benzylguanine/1,3-bis(2-chloroethyl)-1-nitrosourea (BG/BCNU) treatment has been devised.

78 mulation of 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU), an effective agent used in the treat

79 trosourea ([1-(2-chloroethyl)-3-cyclohexyl-l-nitrosourea]; CCNU) concentrations.

80 A mutation induced by ethyl nitrosourea changed a conserved nucleotide at a splice j

81 Pde6a gene in two mouse models from an ethyl nitrosourea chemical mutagenesis screen.

82 ized the tumors to N,N'-bis(2-chloroethyl)-N-nitrosourea chemotherapy, as measured by reduced biolumi

83 ting antitumor drugs such as 2-chloroethyl-N-nitrosourea (CNU).

84 e development of CDH comes from an N-ethyl-N-nitrosourea -derived mouse strain, eyes2, which has a ho

85 tnatally exposed to the carcinogen N-ethyl-N-nitrosourea developed PTMCs, which closely resembled the

86 MT inhibitor O(6)-benzylguanine (O(6)BG) and nitrosourea drugs such as carmustine and methylating age

87 A single dose of N-ethyl-N-nitrosourea (ENU) during late prenatal or early postnata

88 Treatment with N-ethyl-N-nitrosourea (ENU) efficiently generates single-nucleotid

89 ing a forward genomics approach by N-ethyl-N-nitrosourea (ENU) germline mutagenesis in mice, we ident

90 e mutations with the point mutagen N-ethyl-N-nitrosourea (ENU) is a key strategy for analysing the hu

91 ntional germ-cell mutagenesis with N-ethyl-N-nitrosourea (ENU) is compromised by an inability to moni

92 generated by the chemical mutagen n-ethyl-n-nitrosourea (ENU) mapped a new mutant locus (5772SB) ter

93 neous inflammation) was induced by N-ethyl-N-nitrosourea (ENU) mutagenesis in C57BL/6J mice.

94 Cdh23(nmf308/nmf308) mice produced by the N-nitrosourea (ENU) mutagenesis program were used as an an

95 de, phenotype-driven, large-scale N-ethyl-N--nitrosourea (ENU) mutagenesis screen for dominant mutati

96 We conducted a sensitized N-ethyl-N-nitrosourea (ENU) mutagenesis screen for dominant thromb

97 humans and mice, we established an N-ethyl-N-nitrosourea (ENU) mutagenesis screen to identify modifie

98 t-codon mutation recovered from an N-ethyl-N-nitrosourea (ENU) mutagenesis screen.

99 s identified through a genome-wide N-ethyl-N-nitrosourea (ENU) mutagenesis screen.

100 N-ethyl-N-nitrosourea (ENU) mutagenesis screens in the mouse provi

101 In an N-ethyl N-nitrosourea (ENU) mutagenesis strategy, we identified a

102 vention, we carried out a dominant N-ethyl-N-nitrosourea (ENU) mutagenesis suppressor screen in Mecp2

103 N-ethyl-N-nitrosourea (ENU) mutagenesis was used in the mouse to s

104 phthalmoscopy identified a line of N-ethyl-N-nitrosourea (ENU) mutagenized mice demonstrating retinal

105 or the production of mice carrying N-ethyl-N-nitrosourea (ENU) mutations and their screening for audi

106 Point mutations induced by N -ethyl- N -nitrosourea (ENU) provide a unique mutant resource becau

107 arrow with the chemical carcinogen N-ethyl-N-nitrosourea (ENU) resulted in significantly accelerated

108 a second-generation (G2) dominant N-ethyl-N-nitrosourea (ENU) screen especially designed to detect s

109 ance has been used to sensitize an N-ethyl-N-nitrosourea (ENU) screen to identify novel mutations res

110 nctional IkappaBNS derived from an N-ethyl-N-nitrosourea (ENU) screen, named bumble, to investigate t

111 le to t-AML induced by the alkylator ethyl-N-nitrosourea (ENU) to identify genes that regulate t-AML

112 N-Ethyl, N-nitrosourea (ENU) was used as a probing agent in conjunc

113 pase-9, caspase-3, and bax mutants) to ethyl-nitrosourea (ENU), a known DNA mutagen and neural carcin

114 tagen of choice for mouse has been N-ethyl-N-nitrosourea (ENU), an alkylating agent that mainly cause

115 mice to benzo[a]pyrene (B[a]P) or N-ethyl-N-nitrosourea (ENU), daily for 28 consecutive days, and qu

116 to sublethal gamma-irradiation or N-ethyl-N-nitrosourea (ENU), MLL-CBP mice developed myelomonocytic

117 e mutations induced by the mutagen N-ethyl-N-nitrosourea (ENU), numerous animals died under specific

118 of mice with the alkylating agent, N-ethyl-N-nitrosourea (ENU), regardless of the levels of expressio

119 with a potent DNA alkylating agent, N-ethyl-nitrosourea (ENU), to induce secondary cooperating mutat

120 agenized with the germline mutagen N-ethyl-N-nitrosourea (ENU), we identified a recessive mutation co

121 nse b (pob), was isolated using an N-ethyl N-nitrosourea (ENU)-based screening strategy designed to i

122 Here we report the first cloned N-ethyl-nitrosourea (ENU)-derived mouse model of diabetes.

123 We used N-ethyl-N-nitrosourea (ENU)-exposed Ba/F3-p210(BCR-ABL) cells to c

124 flatoxin B1 (AFB1)-induced, 14% of N-ethyl-N-nitrosourea (ENU)-induced and 12% of spontaneous lung ad

125 In an N-ethyl-N-nitrosourea (ENU)-induced forward genetic screen we disc

126 rrying homozygous and heterozygous N-ethyl-N-nitrosourea (ENU)-induced germline mutations for aberran

127 e developed protocols for creating N-ethyl-N-nitrosourea (ENU)-induced germline mutations in several

128 We identify an N-ethyl-N-nitrosourea (ENU)-induced I23N mutation in the THEMIS pr

129 describe the effects of seven new N-ethyl-N-nitrosourea (ENU)-induced Kitl(Sl) mutations and two pre

130 Here, we describe an N-ethyl-N-nitrosourea (ENU)-induced missense error in the membrane

131 he identification of a hyperactive N-ethyl-N-nitrosourea (ENU)-induced mouse mutant with abnormalitie

132 A new N-ethyl-N-nitrosourea (ENU)-induced mouse recessive mutation, iden

133 N-ethyl-N-nitrosourea (ENU)-induced mutagenesis provides a powerfu

134 We report, using N-ethyl-N-nitrosourea (ENU)-induced mutagenesis, the identificatio

135 In a forward genetic screen of N-ethyl-N-nitrosourea (ENU)-induced mutant mice for aberrant immun

136 with and stabilized GPR89, and an N-ethyl-N-nitrosourea (ENU)-induced mutation (explorer) in Gpr89 p

137 A hitherto unidentified N-ethyl-N-nitrosourea (ENU)-induced mutation affects dorsal root g

138 We describe a novel N-ethyl-N-nitrosourea (ENU)-induced mutation, early doors (Edo), i

139 Catweasel is a novel N-ethyl-N-nitrosourea (ENU)-induced mutation.

140 A screen for N-ethyl-N-nitrosourea (ENU)-induced mutations affecting early deve

141 N-ethyl-N-nitrosourea (ENU)-induced mutations in Adam17 (which is

142 Recessive N-ethyl-N-nitrosourea (ENU)-induced mutations recovered at the fit

143 ains and used the panel to map two N-ethyl-N-nitrosourea (ENU)-induced mutations responsible for visi

144 ongoing forward genetic screen for N-ethyl-N-nitrosourea (ENU)-induced mutations that increase suscep

145 ardation observed in mice carrying N-ethyl-N-nitrosourea (ENU)-induced mutations.

146 phages isolated from mice carrying N-ethyl-N-nitrosourea (ENU)-induced mutations.

147 s and is mutationally activated in N-ethyl-N-nitrosourea (ENU)-induced rodent tumors of the Schwann c

148 resonance imaging (MRI)-localized N-ethyl-N-nitrosourea (ENU)-induced tumors in rat brains with thos

149 A forward genetic screen with N-ethyl-N-nitrosourea (ENU)-mutagenized mice linked IRF2 to inflam

150 ut Oceania, and A20 I325N, from an N-ethyl-N-nitrosourea (ENU)-mutagenized mouse strain.

151 disruption of the Runx1 gene with N-ethyl-N-nitrosourea (ENU).

152 cus of mice that were induced with N-ethyl-N-nitrosourea (ENU).

153 c) cells with the chemical mutagen N-ethyl-N-nitrosourea (ENU).

154 een with the chemical supermutagen N-ethyl-N-nitrosourea (ENU).

155 utant resource employs the mutagen N-ethyl-N-nitrosourea (ENU).

156 ecp2/Y mice after mutagenesis with N-ethyl-N-nitrosourea (ENU).

157 lls after exposure to the alkylator, N-ethyl-nitrosourea (ENU).

158 in C57BL/6 mice using the mutagen N-ethyl-N-nitrosourea (ENU).

159 chain alkylating agents including N-ethyl-N-nitrosourea, ethyl methanesulfonate, N-propyl-N-nitrosou

160 wide allelotyping of early passage N-ethyl-N-nitrosourea-exposed cell populations revealed aberration

161 is end, we identified two separate N-ethyl-N-nitrosourea-generated mouse lines that harbor either a p

162 mers containing 10% 1,3-bis(2-chloroethyl)-1-nitrosourea had significantly improved survival compared

163 the random germ line mutagen ENU (N-ethyl-N-nitrosourea), have disclosed key molecules in the TLR si

164 factors do not predict benefit from adjuvant nitrosourea in malignant gliomas, and long-term survival

165 prevent mammary cancer induced by N-methyl-N-nitrosourea in rats.

166 C57BL/6J mice were given N-methyl-N-nitrosourea in their drinking water and sacrificed after

167 nsferase (AGT), that enhances sensitivity to nitrosoureas in tumor-cell lines and tumor-bearing anima

168 tathione reductase (1,3-bis(2-chloroethyl)-1-nitrosourea) in the presence or absence of FBP (3.5 mM).

169 ry effective in the prevention of N-methyl-N-nitrosourea induced mammary cancers in rats without sign

170 Here, we describe a N-ethyl-N-nitrosourea induced recessive mouse mutant, Ms. T-less,

171 N-Ethyl-N-nitrosourea-induced (ENU-induced) missense mutations in

172 n timing in vivo, we exploited the N-ethyl-N-nitrosourea-induced afterhours mutant Fbxl3(Afh) to stab

173 lassic head blebs mutant and in an N-ethyl-N-nitrosourea-induced allele.

174 ele of the insulin receptor and an N-ethyl-N-nitrosourea-induced alternative splice mutation in the r

175 t of breast cancer using the rat N-methyl-N'-nitrosourea-induced and spontaneous HER-2/neu transgenic

176 The N-Ethyl-N-Nitrosourea-induced germline mutation 3d (Unc3b1(3d/3d))

177 As a consequence of a recessive N-ethyl-N-nitrosourea-induced germline mutation in the P-loop of G

178 We describe two N-ethyl N-nitrosourea-induced hypomorphic missense alleles of Ptip

179 ions in Herc2 in three independent N-ethyl-N-nitrosourea-induced jdf2 mutant alleles, each leading to

180 The perinatal lethal N-ethyl-N-nitrosourea-induced l7Rn6(4234SB) allele contained a non

181 x(+/-) mice develop significantly more ethyl nitrosourea-induced lung tumors and lymphomas in compari

182 The N-ethyl-N-nitrosourea-induced lymphomas spread widely, were exclus

183 eriments were conducted using the 1-methyl-1-nitrosourea-induced mammary cancer model in which rats w

184 s (IC50 = 3.2 microM) and reduced N-methyl-N-nitrosourea-induced mammary tumorigenesis when administe

185 ficantly reduced the incidence of N-methyl-N-nitrosourea-induced mammary tumors in our animal model s

186 p.o. administered resveratrol on N-methyl-N-nitrosourea-induced mammary tumors was studied in female

187 Here we describe Jinx, an N-ethyl-N-nitrosourea-induced MCMV susceptibility mutation that pe

188 ive phenotype that results from an N-ethyl-N-nitrosourea-induced missense mutation in the Tlr9 gene (

189 he cleft secondary palate 1 (csp1) N-ethyl-N-nitrosourea-induced mouse model of non-syndromic cleft p

190 s, Dnah11 and Mks1, in independent N-ethyl-N-nitrosourea-induced mouse mutant lines with heritable re

191 ants, we identified ostes, a novel N-ethyl N-nitrosourea-induced mouse mutant with muscle atrophy.

192 Here we report an N-ethyl-N-nitrosourea-induced mouse mutation, Opdc, which is an is

193 ficiency anemia, as revealed by an N-ethyl-N-nitrosourea-induced mouse phenotype called sublytic.

194 o22 is a mutant mouse produced via N-ethyl-N-nitrosourea-induced mutagenesis that shows sterility wit

195 Adult mice from the N-ethyl-N-nitrosourea-induced mutant mouse line nur5 display tremo

196 Here we describe an N-ethyl-N-nitrosourea-induced mutant mouse, alien (aln), which has

197 Recently, a new N-ethyl-N-nitrosourea-induced mutant named chuzhoi (chz) was isola

198 Hereditary albuminuric N-ethyl-N-nitrosourea-induced mutants were redesignated as Nphrp1

199 ltering mutations from a screen of N-ethyl-N-nitrosourea-induced mutants.

200 ified 'triple D' (3d), a recessive N-ethyl-N-nitrosourea-induced mutation and phenotype in which no s

201 ed immunodeficiency revealed by an N-ethyl-N-nitrosourea-induced mutation called elektra.

202 ection was revealed by a recessive N-ethyl-N-nitrosourea-induced mutation called warmflash (wmfl).

203 d p27(-/-) mice displayed a higher N-ethyl-N-nitrosourea-induced mutation frequency in the colon than

204 As a result of an N-ethyl-N-nitrosourea-induced mutation in the last alpha helix of

205 ineages in mice, resulting from an N-ethyl-N-nitrosourea-induced mutation in the limb region 1-like g

206 Here, we report a novel, N-ethyl-N-nitrosourea-induced mutation that causes a gain of funct

207 orward genetic screen of mice with N-ethyl-N-nitrosourea-induced mutations for defects in adaptive im

208 ) resulting from three independent N-ethyl-N-nitrosourea-induced mutations in host cell factor C2 (Hc

209 The immunovariant N-ethyl-N-nitrosourea-induced mutations Pococurante (Poc) and Lack

210 od for real-time identification of N-ethyl-N-nitrosourea-induced mutations that cause phenotypes in m

211 out a genome-wide screen for novel N-ethyl-N-nitrosourea-induced mutations that give rise to eye and

212 Eleven independent, recessive, N-ethyl-N-nitrosourea-induced mutations that map to a approximatel

213 This process was accelerated by N-ethyl-N-nitrosourea-induced mutations.

214 Na(v)1.8 among mice homozygous for N-ethyl-N-nitrosourea-induced mutations.

215 Here we show that an N-ethyl-N-nitrosourea-induced nonsense mutation of Cd36 (oblivious

216 The recessive N-ethyl-N-nitrosourea-induced phenotype toku is characterized by d

217 vel zebrafish gata1 mutant with an N-ethyl-N-nitrosourea-induced point mutation in the C-finger (gata

218 The 1-methyl-1-nitrosourea-induced rat mammary tumor model system is we

219 flake (flk), an N-ethyl-N-nitrosourea-induced recessive germ line mutation of C57B

220 ncidence and decreased latency of N-methyl-N-nitrosourea-induced thymic lymphoma compared to wild-typ

221 increased incidence of spontaneous and ethyl nitrosourea-induced tumors.

222 Primary mouse hepatocytes harboring an ethyl-nitrosourea-induced, ER-retained mutant LDLR secreted co

223 malignant gliomas within the brain, and that nitrosoureas may have therapeutic benefits in addition t

224 wed by a single i.v. injection of N-methyl-N-nitrosourea (MNU) and chronic androgen stimulation.

225 denocarcinoma with invasion after N-methyl-N-nitrosourea (MNU) and testosterone treatments.

226 ed either by exposure to carcinogens (methyl-nitrosourea (MNU) and urethane) or by genetic activation

227 To determine whether N-methyl-N-nitrosourea (MNU) can induce malignant transformation of

228 a) a single i.v. dose of 50 mg of N-methyl-N-nitrosourea (MNU) per kg body weight, followed by chroni

229 The other is postnatal day (P)0 N-methyl-N-nitrosourea (MNU) treatment.

230 In addition, after exposure to N-methyl-N-nitrosourea (MNU), the latency of mammary tumor developm

231 edominant sites of methylation by N-methyl-N-nitrosourea (MNU), which is used to produce a variety of

232 methyl methanesulfonate (MMS) and N-methyl-N-nitrosourea (MNU), while expression of R137Q in pol beta

233 N-methyl-N-nitrosourea (MNU)-dependent gastric cancer was investiga

234 e component of Cassia seed, in an N-methyl-N-nitrosourea (MNU)-induced mouse model of RP.

235 tive chemopreventive agent in the N-methyl-N-nitrosourea (MNU)-induced rat mammary tumor model.

236 nt mice are highly susceptible to N-methyl-N-nitrosourea (MNU)-induced T lymphomas.

237 )-containing oligonucleotides and N-methyl-N-nitrosourea (MNU)-treated DNA templates by the 3' --> 5'

238 d at 5 weeks of age with 50 mg/kg N-methyl-N-nitrosourea (MNU).

239 ceived a single i.v. injection of N-methyl-N-nitrosourea (MNU; 30 mg/kg body weight).

240 Using N-methyl-N-nitrosourea- (MNU-) modified DNA templates in the HSV-tk

241 ncer drug streptozotocin (SZN) contains an N-nitrosourea moiety constructed from N(omega)-methyl-l-ar

242 Within the Munich, Germany, N-ethyl-N-nitrosourea mouse mutagenesis program, we isolated a dom

243 Our own N-ethyl-N-nitrosourea mutagenesis effort, which recently showed th

244 Using N-ethyl-N-nitrosourea mutagenesis in mice in combination with a sc

245 Using N-ethyl-N-nitrosourea mutagenesis on an alcohol-averse background

246 Mice from a G3 N-ethyl-N-nitrosourea mutagenesis program were screened by indirec

247 lved in hematopoiesis, we performed an ethyl-nitrosourea mutagenesis screen in zebrafish (Danio rerio

248 We have utilized N-ethyl-N-nitrosourea mutagenesis to generate pedigrees of mutagen

249 rward genetic screen in mice using N-ethyl-N-nitrosourea mutagenesis to identify genetic mutations th

250 Using N-ethyl-N-nitrosourea mutagenesis, we generated and characterized

251 ant mouse line 20884, generated by N-ethyl-N-nitrosourea mutagenesis, which is characterized by adult

252 These strains were generated by N-ethyl-N-nitrosourea mutagenesis.

253 Forward genetic screens with ENU (N-ethyl-N-nitrosourea) mutagenesis can facilitate gene discovery,

254 nother coronin 1A mutant during an N-ethyl-N-nitrosourea-mutagenesis screen for T cell-lymphopenic mi

255 In a behavioral screen of N-ethyl-N-nitrosourea mutagenized mice we identified a mutant line

256 mice obtained from the breeding of N-ethyl-N-nitrosourea mutagenized mice were formalin-fixed and sta

257 ree 191 (deficient memory (DM)) of N-ethyl-N-nitrosourea mutagenized mice.

258 igh frequency ultrasound to screen N-ethyl-N-nitrosourea mutagenized mouse fetuses for congenital car

259 A forward genetic screen of N-ethyl-N-nitrosourea mutagenized Xenopus tropicalis has identifie

260 By screening N-ethyl-N-nitrosourea-mutagenized animals for alterations in rhyth

261 germline mutant mice derived from N-ethyl-N-nitrosourea-mutagenized grandsires for intestinal homeos

262 A forward genetic screen with ethyl-N-nitrosourea-mutagenized mice links Gsdmd to the intracel

263 Here we identify, from a screen of N-ethyl-N-nitrosourea-mutagenized mice, a mutation causing both pr

264 a population of G(1) mice born to N-ethyl-N-nitrosourea-mutagenized sires.

265 ird generation mice descended from N-ethyl-N-nitrosourea-mutagenized sires.

266 We screened an ethyl nitrosourea mutant mouse library for IMPase gene (Impa)

267 ) was detected in third-generation N-ethyl-N-nitrosourea-mutated mice that showed defective responses

268 SN1 DNA methylating agents such as the nitrosourea N-methyl-N'-nitro-N-nitrosoguanidine (MNNG)

269 ffects of the methylating agents, N-methyl-N-nitrosourea, N-methyl-N'nitro-N-nitrosoguanidine and met

270 (Cisplatin, Nitrogen Mustard and N-methyl-N-nitrosourea (NMNU/MNU)) within mice either singly or dou

271 n, and invasion and determine the effects of nitrosoureas on these cell movement-related processes.

272 DMS, and MeI but not by SN1 agent N-methyl-N-nitrosourea or by gamma irradiation.

273 ls with the S(N)1 DNA methylators N-methyl-N-nitrosourea or N-methyl-N'-nitro-N-nitrosoguanidine resu

274 reductase (GR) with 1,3-bis[2-chloroethyl]-1-nitrosourea or transfection of macrophages with small in

275 ed with carmustine (1,3-bis(2-chloroethyl)-1-nitrosourea, or BCNU).

276 Sprague-Dawley rats with 50 mg of 1-methyl-1-nitrosourea per kilogram of body weight.

277 were injected i.p. with 50 mg of 1-methyl-1-nitrosourea per kilogram of body weight.

278 N(omega)-methyl-L-arginine to generate an N-nitrosourea product.

279 ltransferase (AGT), has been shown to reduce nitrosourea resistance and, thus, enhance the efficacy o

280 producing tumor regression in patients with nitrosourea-resistant malignant glioma, although stable

281 for a phase II trial of O(6)-BG plus BCNU in nitrosourea-resistant malignant glioma.

282 /scid mice with gamma radiation or N-ethyl-N-nitrosourea resulted in approximately 86% incidence of T

283 The observed nitrosourea sensitivity of MGMT-deficient lines (methyl

284 se excision from DNA exposed to [3H]methyl-N-nitrosourea showed that the purified Nth1 enzyme did not

285 eased cellular resistance to 2-chloroethyl-N-nitrosourea suggests a therapeutic significance for PKC-

286 mutagenesis in C57BL/6J mice using N-ethyl-N-nitrosourea to identify mutations causing high blood glu

287 Nitrosoureas, traditionally viewed as DNA alkylating age

288 Previously, we showed that N-methyl-N-nitrosourea-transformed MCF12F breast epithelial cells e

289 um-transformed MECs (Cd-MECs) and N-methyl-N-nitrosourea-transformed MECs (MNU-MECs) on NSCs.

290 ing in first-generation progeny of N-ethyl-N-nitrosourea-treated mice, involving 23 essential immune

291 ATP:Pi ratios after 1,3-bis(2-chloroethyl)-1-nitrosourea treatment indicate improved bioenergetic sta

292 uanine induced by chemotherapeutic N-alkyl N-nitrosourea-type drugs, e.g. 1,3-bis(2-chloroethyl)-1-ni

293 uced by the DNA methylating agent N-methyl-N-nitrosourea was also shown to be hMSH2-dependent.

294 Chemical mutagenesis with N-methyl-N-nitrosourea was employed to study the pattern of mutatio

295 Using N-ethyl-N-nitrosourea, we induced a germline mutation called Lps2,

296 cell resistance to 1,3-bis(2-chloroethyl)-1-nitrosourea, we performed a novel dose escalation clinic

297 is more potent than N,N-bis(2-chloroethyl)-N-nitrosourea, which is currently the most commonly employ

298 exocyclic ring and are formed by chloroethyl nitrosoureas, which are used in cancer therapy.

299 otoxic effects of alkylating agents, such as nitrosoureas, which play a central role in the treatment

300 cells to killing by 1,3-bis(2-chloroethyl)-1-nitrosourea, with O6-benzyl-3'-O-(gamma-folyl)-2'-deoxyg